1-苄基-3-吡咯烷基甲烷磺酸酯 | 114715-35-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-苄基-3-吡咯烷基甲烷磺酸酯
• 英文名称: (3R)-1-benzyl-3-methanesulfonyloxy pyrrolidine
• 英文别名: (R)-1-benzyl-3-mesyloxypyrrolidine；(R)-1-benzyl-3-pyrrolidinol methanesulfonate；(R)-1-benzylpyrrolidin-3-yl methanesulfonate；(R)-3-methanesulfonyloxy-1-(phenylmethyl)-pyrrolidine；(R)-methanesulfonic acid 1-benzylpyrrolidin-3yl ester；(3R)-1-benzyl-3-[(methylsulfonyl)oxy]pyrrolidine；(3R)-1-benzylpyrrolidin-3-yl methanesulfonate；3-Pyrrolidinol, 1-(phenylmethyl)-, 3-methanesulfonate, (3R)-；[(3R)-1-benzylpyrrolidin-3-yl] methanesulfonate
• CAS: 114715-35-4
• 化学式: C₁₂H₁₇NO₃S
• 分子量: 255.338
• InChiKey: NZIDTDIDEPGKHB-GFCCVEGCSA-N

物化性质

• 沸点：
  398.6±31.0 °C(Predicted)
• 密度：
  1.25±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-苄基-3-吡咯烷基甲烷磺酸酯 在 lithium aluminium tetrahydride 、 sodium azide 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 (S)-(-)-1-苄基-3-(叔丁氧羰基氨基)吡咯烷
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of Naphthamides as Dopamine D₃ Receptor Ligands

  摘要：

  A series of naphthamides were synthesized, and the affinities of these compounds were determined for dopamine D-2 and D-3 receptors using radioligand binding techniques. The naphthamide compounds that were prepared include N-(1-alkylpiperidin-4-yl)-4-bromo-1-methoxy-2-naphthamides (1-6), (S)-N-(1-alkylpyrrolidin-3-yl)-4-bromo-1-methoxy-2-naphthamides (7-12), (R)-N-(1-alkylpyrrolidin-3-yl)-4-bromo-1-methoxy-2-naphthamides (13-18), (S)-N-(1-alkyl-2-pyrrolidinylmethyl)-4-bromo-1-methoxy-2-naphthamides (19 -25), (R)-N-(1-alkyl-2-pyrrolidinylmethyl)-4-bromo-1-methoxy-2-naphthamides (26-31), and N-(9-alkyl-9-azabicyclo-[3.3.1]nonan-3 beta -yl)-4- bromo-1-methoxy-2-naphthamides (32, 33). The results of in vitro radioligand binding studies indicated that the majority of the naphthamide analogues bound with high affinity at both the D-2 and D-3 dopamine receptor subtypes and most of the compounds demonstrated some selectivity for the dopamine D-3 dopamine receptor subtype. These results demonstrated that both the structure of the central amine moiety (piperidine, pyrrolidine, and 9-azabicyclo[3.3.1]nonane) ring and the N-(alkyl) substitution on the amine significantly effects the binding affinity at D-2 and D-3 dopamine receptors. The bulkiness of the N-(1-alkyl) substituent was found to (a) have no effect on pharmacologic selectivity, (b) increase the affinity at Ds receptors, or (c) decrease the affinity at D-2 receptors. The most potent analogue in this series was (S)-N-(1-cycloheptylpyrrolidin-3-yl)-4-bromo-1-methoxy-2-naphthamide (10), which had equilibrium dissociation (K-i) values of 1.8 and 0.2 nM for D-2 and D-3 receptors, respectively. The most selective analogue was (R)-N-(1-cycloheptyl-2-pyrrolidinylmethyl)-4-bromo-1-methoxy-2-naphthamide (30), which had K-i values of 62.8 and 2.4 nM for D-2 and D-3 receptors, respectively. Radioligand binding results for sigma receptors indicated that the structure of the amine moiety and the N-(l-alkyl) substitutions also significantly influence the affinity and selectivity of these compounds at the sigma (1) and sigma (2) sigma receptor subtypes. The two naphthamides containing a 9-azabicyclo[3.3.1]nonan-3 beta -yl central ring were found to be selective for sigma (2) receptors.

  DOI：

  10.1021/jm0100077
• 作为产物：
  描述：

  (2S)-2-[bis(phenylmethyl)amino]-1,4-butanediol 在 palladium dihydroxide 氢气 、 三乙胺 作用下， 以 四氢呋喃 、 乙醇 为溶剂， -25.0 ℃ 、101.01 kPa 条件下， 反应 1.83h， 生成 1-苄基-3-吡咯烷基甲烷磺酸酯
  参考文献：
  名称：

  A Practical Ex-Chiral-Pool Synthesis of β-Proline and Homo-β-Proline

  摘要：

  DOI：

  10.1055/s-1998-2185

文献信息

• [EN] SORDARIN DERIVATIVES FOR PREVENTING OR TREATING INFECTIOUS DISEASES CAUSED BY PATHOGENIC MICROORGANISMS<br/>[FR] DÉRIVÉS DE SORDARINE POUR PRÉVENIR OU TRAITER DES MALADIES INFECTIEUSES CAUSÉES PAR DES MICRO-ORGANISMES PATHOGÈNES
  申请人：ASTELLAS PHARMA INC

  公开号：WO2009131246A1

  公开（公告）日：2009-10-29

  This invention relates to a new sordarin derivative or a pharmaceutically acceptable salt thereof, which has antimicrobial activities (especially, antifungal activities), to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases in a human being or an animal.

  这项发明涉及一种新的索达林衍生物或其药用可接受的盐，该衍生物具有抗菌活性（特别是抗真菌活性），其制备方法，包含该衍生物的药物组合物，以及用于预防或治疗人类或动物传染性疾病的方法。
• Synthesis of beta-proline like derivatives and their evaluation as sodium channel blockers
  作者：Marilena Muraglia、Carlo Franchini、Filomena Corbo、Antonio Scilimati、Vincenzo Tortorella、Maria Stefania Sinicropi、Annamaria De Luca、Michela De Bellis、Diana Conte Camerino

  DOI：10.1002/jhet.5570440519

  日期：2007.9

  A simple and convenient procedure for the preparation of beta-proline like derivatives in their racemic and optically active forms has been reported. The compounds have been screened for their potential activity as sodium channel blockers.

  已经报道了制备外消旋和旋光形式的β-脯氨酸样衍生物的简单方便的方法。已经筛选了化合物作为钠通道阻滞剂的潜在活性。
• Novel farnesyl protein transferase inhibitors as antitumor agents
  申请人：——

  公开号：US20030229099A1

  公开（公告）日：2003-12-11

  Disclosed are novel tricyclic compounds represented by the formula (1.0): 1 or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising compounds of formula 1.0. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

  揭示了由式（1.0）表示的新型三环化合物： 1 或其药学上可接受的盐或溶剂。这些化合物对抑制法尼基蛋白转移酶具有用处。还揭示了包括式1.0化合物的药物组合物。还揭示了使用式1.0化合物治疗癌症的方法。
• [EN] 1-SUBSTITUTED-3-PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE 1-SUBSTITUES-3-PYRROLIDINES COMME ANTAGONISTES DE RECEPTEURS MUSCARINIQUES
  申请人：RANBAXY LAB LTD

  公开号：WO2004056767A1

  公开（公告）日：2004-07-08

  This invention generally relates to the derivatives of 1 -substituted-3 -pyrroli dines having the structure of Formula (I): The compounds of this invention can function as..muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of the compounds of the present invention. pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.

  这项发明通常涉及具有式（I）结构的1-取代-3-吡咯啉二烯衍生物：本发明的化合物可以作为..毒蕈碱受体拮抗剂，可用于治疗通过毒蕈碱受体介导的呼吸系统、泌尿系统和消化系统的各种疾病。该发明还涉及制备本发明化合物的方法、含有本发明化合物的药物组合物以及治疗通过毒蕈碱受体介导的疾病的方法。
• Process for preparing 2-phenyl-3-naphthylpropionic acid derivatives
  申请人：Daiichi Pharmaceutical Co., Ltd.

  公开号：US06252088B1

  公开（公告）日：2001-06-26

  A process for preparing a compound represented by general formulae (5) and (6) in the following reaction scheme or salts thereof, wherein R1 represents a protective group for a nitrogen atom; R2 represents a methanesulfonyl group or p-toluenesulfonyl group; R3 represents a hydrogen atom, an aralkyl group, or an alkyl group having 1 to 6 carbon atoms; and X represents a halogen atom. The above process is useful as an industrial process for preparing intermediates of anticoagulant aromatic amidine derivatives described in Japanese Patent Application Laid-Open (kokai) No. 208946/1993.

  一种制备以下反应方案中的通用化合物（5）和（6）或其盐的方法，其中R1代表氮原子的保护基团；R2代表甲磺酰基团或对甲苯磺酰基团；R3代表氢原子、芳基烷基或具有1至6个碳原子的烷基；X代表卤素原子。上述方法可用作制备日本专利申请公开（公开号208946/1993）中描述的抗凝血芳香胺衍生物中间体的工业过程。